Nimodipine

Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders[1].

Product Specifications

CAS Number

[66085-59-4]

Product Name Alternative

BAY-e 9736

UNSPSC

12352005

Hazard Statement

H302

Target

Autophagy; Calcium Channel

Type

Reference compound

Related Pathways

Autophagy; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Nimodipine.html

Concentration

10mM

Purity

99.86

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=C(C)NC(C)=C(C(OC(C)C)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCOC

Molecular Formula

C21H26N2O7

Molecular Weight

418.44

Precautions

H302

References & Citations

[1]Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989) .|[2] Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34 (5) :932-938.|[3]Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2 (1) :61-72.